Public health impact of current and proposed age-expanded perennial malaria chemoprevention: a modelling study.

ABSTRACT: In 2022, the World Health Organization extended their guidelines for perennial malaria chemoprevention (PMC) from infants to children up to 24 months old. However, evidence for PMC's public health impact is primarily limited to children under 15 months. Further research is needed to assess the public health impact and cost-effectiveness of PMC, and the added benefit of further age-expansion. We integrated an individual-based model of malaria with pharmacological models of drug action to address these questions for PMC and a proposed age-expanded schedule (referred as PMC+, for children 03-36 months). Across malaria prevalence settings of 5-70% and different drug sensitivity assumptions, we predicted PMC and PMC+'s median efficacy (interquartile range) of 18.6% (12.2-25.0%) and 21.9% (14.3-

SUBMITTER: Sen S 

PROVIDER: S-EPMC11947144 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature